Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lee's Pharm Acquires China Rights to Cancer mAb from Sorrento in $50 Million Deal

publication date: Oct 6, 2014
Lee's Pharm in-licensed China rights to a immune-oncological anti-PD-L1 monoclonal antibody from Sorrento Therapeutics of San Diego. Although the drug candidate is in pre-clinical development, Lee's says it expects to start a China Phase I trial of STI-A1014 in 2015. Lee's made an unspecified upfront payment, and will be liable for up to $46 million in milestones plus royalties on revenues, which range from high-single to double digits. Lee's will also purchase $3.6 million in Sorrento's stock at a "substantial" premium to the current market price. More details....

Stock Symbol: (HK: 0950) (NSDQ: SRNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital